{
    "Allocation": "N/A",
    "CompleteTime": 36,
    "DesignModel": "Single Group Assignment",
    "DrugInformation": {
        "ArmGroupList": [
            {
                "ArmGroupDescription": "generic single tablet taf/ftc/dtg:   , ",
                "ArmGroupLabel": "generic single tablet regimen of tenofovir alafenamide/e",
                "ArmGroupType": "Other",
                "InterventionDescription": [
                    {
                        "Dosage": "",
                        "DrugName": "generic single tablet taf/ftc/dtg",
                        "Duration": "",
                        "HowToTake": ""
                    }
                ],
                "InterventionList": {
                    "ArmGroupInterventionName": [
                        "Drug: generic single tablet TAF/FTC/DTG"
                    ]
                }
            }
        ]
    },
    "Enrollment": "190",
    "InterventionName": "FTC",
    "Masking": "None (Open Label)",
    "NCTID": "NCT03727152",
    "Objective": "Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir",
    "OfficialTitle": "Maintenance of Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir in Virologically Suppressed HIV-infected Adults",
    "PopulationBox": {
        "Condition": "HIV",
        "Gender": "All",
        "HealthyCondition": "No",
        "MaxAge": "",
        "MinAge": "18 Years",
        "Participant": "190"
    },
    "PopulationRatio": "",
    "Title": "Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir",
    "WashoutPeriod": ""
}